The Measure of Plasma Concentrations Is Crucial in Managing Dabigatran Treatment in Non-Valvular Atrial Fibrillation

被引：0
|
作者：
Iosub, Diana [1 ]
Trotti, Rosa [2 ]
Piovella, Franco [2 ]
机构：
[1] Fdn IRCCS Policlin San Matteo, Pavia, Italy
[2] Fdn IRCCS Ist Neurol Nazl Casimiro Mondino, Pavia, Italy
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation
    Zhu Zhu
    Zhu Shen
    Aiming Shi
    Cunjin Su
    Jiaojiao Mao
    Hong Tao
    Feng Xu
    Zhanhong Hu
    Jie Pan
    Heart and Vessels, 2022, 37 : 821 - 827
  • [2] Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation
    Zhu, Zhu
    Shen, Zhu
    Shi, Aiming
    Su, Cunjin
    Mao, Jiaojiao
    Tao, Hong
    Xu, Feng
    Hu, Zhanhong
    Pan, Jie
    HEART AND VESSELS, 2022, 37 (05) : 821 - 827
  • [3] Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
    Bengtson, Lindsay G. S.
    Lutsey, Pamela L.
    Chen, Lin Y.
    MacLehose, Richard F.
    Alonso, Alvaro
    JOURNAL OF CARDIOLOGY, 2017, 69 (5-6) : 868 - 876
  • [4] Benefit–Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation
    Sascha Meyer dos Santos
    Sebastian Harder
    Drug Safety, 2014, 37 : 295 - 307
  • [5] Factors influencing physicians' selection of dabigatran in non-valvular atrial fibrillation
    Huang, Cindy
    Siu, Michele
    Vu, Lily
    Wong, Soo
    Shin, Jaekyu
    PHARMACOTHERAPY, 2012, 32 (10): : E186 - E186
  • [6] Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation
    Huang, Cindy
    Siu, Michele
    Vu, Lily
    Wong, Soo
    Shin, Jaekyu
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2013, 19 (05) : 938 - 943
  • [7] Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation
    Tsuda, Keisuke
    Natori, Tatsunori
    Shimizu, Mie
    Ishigaku, Yoko
    Oi, Kiyotaka
    Narumi, Shinsuke
    Kamada, Asami
    Yoshida, Makiko
    Oura, Kazumasa
    Maeda, Tetsuya
    Terayama, Yasuo
    THROMBOSIS RESEARCH, 2020, 189 : 1 - 4
  • [8] Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation
    Tomita, Hideharu
    Araki, Takuya
    Kadokami, Toshiaki
    Yamada, Satoshi
    Nakamura, Ryo
    Imamura, Yoshihiro
    Fukuyama, Takaya
    Nagano, Daisuke
    Hashimoto, Tomoya
    Uematsu, Akiko
    Hosokawa, Kazuya
    Yamamoto, Koujirou
    Ueda, Shin-ichiro
    Ando, Shin-ichi
    THROMBOSIS RESEARCH, 2016, 145 : 100 - 106
  • [9] Benefit-Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation
    dos Santos, Sascha Meyer
    Harder, Sebastian
    DRUG SAFETY, 2014, 37 (05) : 295 - 307
  • [10] Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation
    Hao, Li
    Zhong, Jing-quan
    Zhang, Wei
    Rong, Bing
    Xie, Fei
    Wang, Jun-tao
    Yue, Xin
    Zheng, Zhao-tong
    Zhu, Qing
    Zhang, Yun
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 190 : 63 - 66
12345